Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pentabio
- Development stage
- Phase 3
- Lead developer
- Bio Farma
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Pentabio (often referred to as Pentavalen in Indonesia) is a pentavalent combination vaccine developed and manufactured by PT Bio Farma. It is a biological product containing five active antigens: diphtheria toxoid, tetanus toxoid, whole-cell pertussis (wP), recombinant hepatitis B surface antigen (HBsAg), and Haemophilus influenzae type b (Hib) conjugate. The vaccine is indicated for active immunization against diphtheria, tetanus, pertussis, hepatitis B, and invasive diseases caused by Hib in infants and children. It is provided as a ready-to-use liquid for intramuscular administration. Pentabio received WHO prequalification in December 2014, making it eligible for global procurement by organizations such as UNICEF and PAHO. A Phase 2/3 clinical trial was conducted to evaluate antibody persistence and immune response to a booster dose in Indonesian children.
- Brand names
- Pentabio
- Other names
- PentavalenDTP-HB-Hib vaccinePentavalent vaccine
02
Targets
BCR (Immunoglobulin G B Cell Receptor)PRR (Pattern recognition receptors)γδ TCR (T-cell receptor)Diphtheria toxinHBsAg (Hepatitis B surface antigen)
Beyond the preview
Go deeper on Pentabio.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Pentabio.